References
- Biegler, P., & Vargas, P. (2013). Ban the sunset? Nonpropositional content and regulation of pharmaceutical advertising. American Journal of Bioethics, 13(5), 3–13.
- Gagnon, M.-A., & Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine, 5(1), e1.
- Greene, J., & Herzberg, D. (2010, May). Hidden in plain sight: Marketing prescription drugs to consumers in the twentieth century. American Journal of Public Health, 100(5), 793–803.
- U.S. Department of Health and Human Services, Food and Drug Administration. (2013). Keeping watch over direct-to-consumer ads. Retrieved from http:// www.fda.gov/ForConsumers/ConsumerUpdates/ ucm107170.htm
- United States Congressional Budget Office. (2011). Potential effects of a ban on direct-to-consumer advertising of new prescription drugs. Washington, DC.
- United States Government Accountability Office. (2002). FDA oversight of direct-to-consumer advertising has its limitations. Retrieved from http://www.gao. gov/new.items/d03177.pdf
- Ventola, C. L. (2011, October). Direct-to-consumer pharmaceutical advertising: Therapeutic or toxic? Pharmacy and Therapeutics, 36(10), 669–674.